Advertisement

Q&A

Expert Q&A
Gulsen Ozen
Expert Q&A
Statin Use in Patients With RA to Reduce CVD, Type 2 Diabetes Risk
12/09/2023
Gulsen Ozen, MD, answers questions about her team’s research in the use of statins to help reduce the risk of cardiovascular disease and type 2 diabetes in individuals with rheumatoid arthritis.
12/09/2023
expert Q&A
valentina celoria headshot
expert Q&A
Psoriatic Disease and the Human Microbiome
12/06/2023
In this Q and A, Valentina Celoria, MD, discusses the relationship between the human microbiome and psoriatic disease, as well as what this relationship may mean for future treatments.
12/06/2023
Expert Q&A
shutterstock
Expert Q&A
The Use of Blood Cell Count for Asthma Phenotype Identification
12/05/2023
In this Q and A, lead author Andriana Papaioannou, MD, PhD, discusses the role that identification of asthma phenotypes has in asthma diagnosis and management, the potential use of a complete blood cell...
12/05/2023
expert Q&A
Nader shaikh
expert Q&A
Short-Course vs Standard-Course Treatment for UTIs In Pediatric Patients
12/01/2023

Nader Shaik, MD, MPH

Nader Shaik, MD, MPH
In this Q and A, Nader Shaik, MD, MPH, discusses the results of his team's recent study examining treatment failure rates of short-course vs standard-course antimicrobial therapy for the treatment of...
12/01/2023
Expert Q&A
Robin Gal
Expert Q&A
Using a Telehealth Model in the Management of Patients With Diabetes
11/30/2023

Robin Gal, MSPH, CCRA • Grazia Aleppo, MD, FACE, FACP •  Teresa McArthur, MS, RD, CDCES

Robin Gal, MSPH, CCRA • Grazia Aleppo, MD, FACE, FACP •  Teresa McArthur, MS, RD, CDCES...
In this Q and A, Robin Gal, MSPH, CCRA, Grazia Aleppo, MD, FACE, FACP, and Teresa McArther, MS, RD, CDES answer questions about their study that investigated the use of a virtual clinic to support...
11/30/2023
expert Q&A
emile d'angremont
expert Q&A
Cholinesterase Inhibitors for Neuropsychiatric Symptoms in Alzheimer Disease, Parkinson Disease
11/27/2023

Emile d’Angremont, MSc

Emile d’Angremont, MSc
In this interview, Emile d’Angremont, MSc, discusses the results of a recent study examining the use of cholinesterase inhibitors for the management of psychotic symptoms among patients with...
11/27/2023
Expert Q&A
Stephen Biehl, RRT, RPFT
Expert Q&A
Race, Ethnicity in Pulmonary Function Test Interpretation
11/09/2023

Stephen Biehl, RRT, RPFT

Stephen Biehl, RRT, RPFT
In this Q and A, Stephen Biehl, RRT, RPFT, answers questions about the guidelines from the American Thoracic Society on the use of race-specific equations in the interpretation of pulmonary function tests,...
11/09/2023
Expert Q&A
Elmar Joura, MD
Expert Q&A
Long-Term Follow-Up Data on Sustained Immunogenicity, Safety for 9-Valent Human Papillomavirus Vaccine
11/08/2023

Elmar A. Joura, MD

Elmar A. Joura, MD
In this interview, Elmar Joura, MD, answers questions about the long-term follow-up data on sustained immunogenicity and safety for the 9-valent human papillomavirus (HPV) vaccine, including indications,...
11/08/2023
expert Q&A
margaret lampe
expert Q&A
Achieving Perinatal HIV Elimination Goals
10/31/2023

Margaret A. Lampe, RN, MPH

Margaret A. Lampe, RN, MPH
In this expert Q&A, Margaret A. Lampe, RN, MsC, discusses the elimination of perinatal HIV transmission, elimination goals set out by the CDC, next steps for research, and more.
10/31/2023
Expert Q&A
Ian Bouligny
Expert Q&A
Can Venetoclax-Based Strategies Be Used in Treating Patients With Secondary-Type AML Mutations?
10/30/2023

Ian Bouligny, MD

Ian Bouligny, MD
In this interview, Ian Bouligny, MD, answers questions about his team’s research that sought to determine the use of venetoclax-based strategies in patients with newly diagnosed secondary-type mutations of...
10/30/2023